The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Medulloblastoma


Psychiatry related information on Medulloblastoma

  • We report a confirmatory case of sudden, severe visual loss in association with cerebellar mutism after resection of a midline medulloblastoma in a 7-year-old [7].

High impact information on Medulloblastoma


Chemical compound and disease context of Medulloblastoma


Biological context of Medulloblastoma


Anatomical context of Medulloblastoma


Gene context of Medulloblastoma

  • Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease [2].
  • The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation [24].
  • In human medulloblastomas reverse transcription-PCR for Shh and Notch targets revealed activation of both of these pathways in most tumors when compared with normal cerebellum [25].
  • Mutations in CTNNB1 were found exclusively among medulloblastomas that demonstrated nuclear beta-catenin immunoreactivity, but no evidence of APC mutation was found in these cases [26].
  • Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched [27].
  • Reintroduction of SGNE1 into the medulloblastoma cell line D283Med led to a significant growth suppression and reduced colony formation [28].
  • Adenoviral vector-mediated expression of DKK1 in medulloblastoma cells increased apoptosis fourfold (P < 0.001) [29].
  • A molecular risk stratification model for medulloblastoma patients is proposed based on the signature of MYC, LDHB, and CCNB1 expression [30].
  • We use a mouse model of Ptch1 heterozygosity to reveal a critical tumor suppressor function for Hic1 in medulloblastoma [31].
  • COL1A2 status distinguished infant medulloblastomas of the desmoplastic histopathological subtype, indicating that distinct molecular pathogenesis may underlie these tumors and their more favorable prognosis [32].
  • GSTM1 and GSTT1 polymorphisms may predict adverse events, including cognitive impairment after therapy, in patients with medulloblastoma [33].

Analytical, diagnostic and therapeutic context of Medulloblastoma


  1. Mutations in SUFU predispose to medulloblastoma. Taylor, M.D., Liu, L., Raffel, C., Hui, C.C., Mainprize, T.G., Zhang, X., Agatep, R., Chiappa, S., Gao, L., Lowrance, A., Hao, A., Goldstein, A.M., Stavrou, T., Scherer, S.W., Dura, W.T., Wainwright, B., Squire, J.A., Rutka, J.T., Hogg, D. Nat. Genet. (2002) [Pubmed]
  2. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. MacDonald, T.J., Brown, K.M., LaFleur, B., Peterson, K., Lawlor, C., Chen, Y., Packer, R.J., Cogen, P., Stephan, D.A. Nat. Genet. (2001) [Pubmed]
  3. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. Friedman, H.S., Colvin, O.M., Griffith, O.W., Lippitz, B., Elion, G.B., Schold, S.C., Hilton, J., Bigner, D.D. J. Natl. Cancer Inst. (1989) [Pubmed]
  4. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. Friedman, H.S., Dolan, M.E., Moschel, R.C., Pegg, A.E., Felker, G.M., Rich, J., Bigner, D.D., Schold, S.C. J. Natl. Cancer Inst. (1992) [Pubmed]
  5. Expression of human neurotropic polyomavirus JCV late gene product agnoprotein in human medulloblastoma. Del Valle, L., Gordon, J., Enam, S., Delbue, S., Croul, S., Abraham, S., Radhakrishnan, S., Assimakopoulou, M., Katsetos, C.D., Khalili, K. J. Natl. Cancer Inst. (2002) [Pubmed]
  6. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. de Bont, J.M., Kros, J.M., Passier, M.M., Reddingius, R.E., Sillevis Smitt, P.A., Luider, T.M., den Boer, M.L., Pieters, R. Neuro-oncology (2008) [Pubmed]
  7. Visual disturbance associated with postoperative cerebellar mutism. Daniels, S.R., Moores, L.E., DiFazio, M.P. Pediatric neurology. (2005) [Pubmed]
  8. PDGFRB is overexpressed in metastatic medulloblastoma. Gilbertson, R.J., Clifford, S.C. Nat. Genet. (2003) [Pubmed]
  9. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Mollenhauer, J., Wiemann, S., Scheurlen, W., Korn, B., Hayashi, Y., Wilgenbus, K.K., von Deimling, A., Poustka, A. Nat. Genet. (1997) [Pubmed]
  10. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Hallahan, A.R., Pritchard, J.I., Chandraratna, R.A., Ellenbogen, R.G., Geyer, J.R., Overland, R.P., Strand, A.D., Tapscott, S.J., Olson, J.M. Nat. Med. (2003) [Pubmed]
  11. Deregulated expression of PAX5 in medulloblastoma. Kozmik, Z., Sure, U., Rüedi, D., Busslinger, M., Aguzzi, A. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  12. Carboplatin and cisplatin in medulloblastoma at diagnosis: "comparable efficacy?". Mastrangelo, R., Lasorella, A., Tornesello, A., Riccardi, R. J. Clin. Oncol. (1996) [Pubmed]
  13. Cyclophosphamide resistance in medulloblastoma. Friedman, H.S., Colvin, O.M., Kaufmann, S.H., Ludeman, S.M., Bullock, N., Bigner, D.D., Griffith, O.W. Cancer Res. (1992) [Pubmed]
  14. Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Urbanska, K., Trojanek, J., Del Valle, L., Eldeen, M.B., Hofmann, F., Garcia-Echeverria, C., Khalili, K., Reiss, K. Oncogene (2007) [Pubmed]
  15. REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma. Di Marcotullio, L., Ferretti, E., De Smaele, E., Argenti, B., Mincione, C., Zazzeroni, F., Gallo, R., Masuelli, L., Napolitano, M., Maroder, M., Modesti, A., Giangaspero, F., Screpanti, I., Alesse, E., Gulino, A. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  16. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Su, X., Gopalakrishnan, V., Stearns, D., Aldape, K., Lang, F.F., Fuller, G., Snyder, E., Eberhart, C.G., Majumder, S. Mol. Cell. Biol. (2006) [Pubmed]
  17. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Smyth, I., Narang, M.A., Evans, T., Heimann, C., Nakamura, Y., Chenevix-Trench, G., Pietsch, T., Wicking, C., Wainwright, B.J. Hum. Mol. Genet. (1999) [Pubmed]
  18. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Di, C., Liao, S., Adamson, D.C., Parrett, T.J., Broderick, D.K., Shi, Q., Lengauer, C., Cummins, J.M., Velculescu, V.E., Fults, D.W., McLendon, R.E., Bigner, D.D., Yan, H. Cancer Res. (2005) [Pubmed]
  19. Does growth hormone cause relapse of brain tumours? Clayton, P.E., Shalet, S.M., Gattamaneni, H.R., Price, D.A. Lancet (1987) [Pubmed]
  20. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. Dunkel, I.J., Boyett, J.M., Yates, A., Rosenblum, M., Garvin, J.H., Bostrom, B.C., Goldman, S., Sender, L.S., Gardner, S.L., Li, H., Allen, J.C., Finlay, J.L. J. Clin. Oncol. (1998) [Pubmed]
  21. Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies. Sasai, K., Romer, J.T., Lee, Y., Finkelstein, D., Fuller, C., McKinnon, P.J., Curran, T. Cancer Res. (2006) [Pubmed]
  22. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Zurawel, R.H., Chiappa, S.A., Allen, C., Raffel, C. Cancer Res. (1998) [Pubmed]
  23. A novel role for extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death. Sturla, L.M., Cowan, C.W., Guenther, L., Castellino, R.C., Kim, J.Y., Pomeroy, S.L. Cancer Res. (2005) [Pubmed]
  24. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Uziel, T., Zindy, F., Xie, S., Lee, Y., Forget, A., Magdaleno, S., Rehg, J.E., Calabrese, C., Solecki, D., Eberhart, C.G., Sherr, S.E., Plimmer, S., Clifford, S.C., Hatten, M.E., McKinnon, P.J., Gilbertson, R.J., Curran, T., Sherr, C.J., Roussel, M.F. Genes Dev. (2005) [Pubmed]
  25. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Hallahan, A.R., Pritchard, J.I., Hansen, S., Benson, M., Stoeck, J., Hatton, B.A., Russell, T.L., Ellenbogen, R.G., Bernstein, I.D., Beachy, P.A., Olson, J.M. Cancer Res. (2004) [Pubmed]
  26. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. Ellison, D.W., Onilude, O.E., Lindsey, J.C., Lusher, M.E., Weston, C.L., Taylor, R.E., Pearson, A.D., Clifford, S.C. J. Clin. Oncol. (2005) [Pubmed]
  27. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Wetmore, C., Eberhart, D.E., Curran, T. Cancer Res. (2001) [Pubmed]
  28. SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas. Waha, A., Koch, A., Hartmann, W., Milde, U., Felsberg, J., Hübner, A., Mikeska, T., Goodyer, C.G., Sörensen, N., Lindberg, I., Wiestler, O.D., Pietsch, T., Waha, A. Oncogene (2007) [Pubmed]
  29. Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Vibhakar, R., Foltz, G., Yoon, J.G., Field, L., Lee, H., Ryu, G.Y., Pierson, J., Davidson, B., Madan, A. Neuro-oncology (2007) [Pubmed]
  30. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. de Haas, T., Hasselt, N., Troost, D., Caron, H., Popovic, M., Zadravec-Zaletel, L., Grajkowska, W., Perek, M., Osterheld, M.C., Ellison, D., Baas, F., Versteeg, R., Kool, M. Clin. Cancer Res. (2008) [Pubmed]
  31. Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Briggs, K.J., Corcoran-Schwartz, I.M., Zhang, W., Harcke, T., Devereux, W.L., Baylin, S.B., Eberhart, C.G., Watkins, D.N. Genes Dev. (2008) [Pubmed]
  32. Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Anderton, J.A., Lindsey, J.C., Lusher, M.E., Gilbertson, R.J., Bailey, S., Ellison, D.W., Clifford, S.C. Neuro-oncology (2008) [Pubmed]
  33. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Barahmani, N., Carpentieri, S., Li, X.N., Wang, T., Cao, Y., Howe, L., Kilburn, L., Chintagumpala, M., Lau, C., Okcu, M.F. Neuro-oncology (2009) [Pubmed]
  34. Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. Friedman, H.S., Schold, S.C., Mahaley, M.S., Colvin, O.M., Oakes, W.J., Vick, N.A., Burger, P.C., Bigner, S.H., Borowitz, M., Halperin, E.C. J. Clin. Oncol. (1989) [Pubmed]
  35. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. Mendrzyk, F., Radlwimmer, B., Joos, S., Kokocinski, F., Benner, A., Stange, D.E., Neben, K., Fiegler, H., Carter, N.P., Reifenberger, G., Korshunov, A., Lichter, P. J. Clin. Oncol. (2005) [Pubmed]
  36. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. Fouladi, M., Chintagumpala, M., Laningham, F.H., Ashley, D., Kellie, S.J., Langston, J.W., McCluggage, C.W., Woo, S., Kocak, M., Krull, K., Kun, L.E., Mulhern, R.K., Gajjar, A. J. Clin. Oncol. (2004) [Pubmed]
  37. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Friedman, H.S., Colvin, O.M., Skapek, S.X., Ludeman, S.M., Elion, G.B., Schold, S.C., Jacobsen, P.F., Muhlbaier, L.H., Bigner, D.D. Cancer Res. (1988) [Pubmed]
WikiGenes - Universities